证券代码：600566 证券简称：济川药业 公告编号： 2025-093 湖北济川药业股份有限公司 关于 2022 年限制性股票与股票期权激励计划 部分限制性股票回购注销实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：湖北济川药业股份有限公司（以下简称"公司"）2025 年 9 月 9 日召开第十届董事会第十七次会议，审议通过了《关于注销部分股票期权并 回购注销部分限制性股票的议案》：（1）由于 3 名激励对象离职，根据《湖北 济川药业股份有限公司 2022 年限制性股票与股票期权激励计划》(以下简称"本 激励计划")的相关规定，拟回购注销上述激励对象已获授但尚未解除限售的首 次授予的限制性股票 6.7 万股。（2）鉴于 5 名激励对象 2022 年度个人绩效考核 不达标，按照本激励计划的规定，公司拟回购注销其已获授但尚未解除限售的首 次授予的限制性股票 10.48 万股。 本次注销股份的有关情况： | 回购股份数量（股） | 注销股份数量（股） | | 注销日期 | | | | | ...

2022 年限制性股票与股票期权激励计划 回购注销部分限制性股票事项 国浩律师（上海）事务所 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: (+86)(21) 5234 1668 传真/Fax: (+86)(21) 5234 1670 网址/Website: http://www.grandall.com.cn 二〇二五年十一月 关于湖北济川药业股份有限公司 | 释 义 2 | | --- | | 律师应当声明的事项 5 | | 正 文 7 | | 一、本次激励计划回购注销事项的批准和授权 7 | | 二、本次回购注销的具体情况 9 | | 三、结论意见 10 | 国浩律师（上海）事务所 法律意见书 释 义 在本法律意见书中，除非上下文另作解释，否则下列简称和术语具有以下 含义： | 公司 | 指 | 湖北济川药业股份有限公司 | | --- | --- | --- | | 本次激励计划 ...

湖北济川药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 证券代码：600566 证券简称：济川药业 公告编号：2025-094 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 28 日 （星期五） 至 12 月 04 日 （星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 jcyy@jumpcan.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 湖北济川药业股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发 布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 12 月 05 日 （星期五） 15:00-16:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本 ...

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-092 湖北济川药业股份有限公司 关于全资子公司开立募集资金现金管理专用结算账户 并利用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 履行的审议程序：湖北济川药业股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第十届董事会第十四次会议，于 2025 年 5 月 16 日召开 2024 年年度股东大会，审议通过了《关于全资子公司利用闲置募集资金和自有资金进 行现金管理的议案》，同意公司在不影响募投项目正常实施并保证募集资金安全 的前提下，使用额度不超过 5.8 亿元（含本数）的闲置募集资金进行现金管理， 投资对象为安全性高、流动性好、有保本约定、投资期限不超过 12 个月的投资 产品，包括但不限于理财产品、结构性存款、定期存款、大额存单等。具体内容 详见公司分别于 2025 年 4 月 26 日、2025 年 5 月 17 日披露于上海证券交易所网 站（http://www.sse.c ...

Core Insights - The flu season in China is expected to peak in late December and early January, leading to increased competition among flu medications [1][3] - Prices for flu medications, particularly for the popular drug Sufo, have started to drop as companies aim to capture market share [1][2] - The market for flu medications in China has surpassed 10 billion yuan, with Oseltamivir holding over 80% market share [4][5] Group 1: Market Dynamics - Sufo, a drug from Roche, was initially priced at 498 yuan per box but has seen a significant reduction to 222.36 yuan after being included in the national medical insurance directory [3] - The supply of Sufo is currently stable, with prices ranging from 239 to 258 yuan in retail pharmacies [2] - The entry of multiple domestic flu medications is intensifying competition, with several new products expected to launch in 2025 [6][7] Group 2: Competitive Landscape - Traditional flu medications like Oseltamivir are facing price pressures due to increased competition and collective procurement policies, with prices dropping significantly [4][5] - The market is seeing a surge in domestic flu drugs, with several companies like Qingfeng Pharmaceutical and Zhongsheng Pharmaceutical launching new products [6][8] - Oseltamivir's market share is projected to decline to 54.8% as more competitors enter the market, with over 70 companies producing the drug [5] Group 3: Regulatory and Development Updates - New flu medications are actively seeking inclusion in the medical insurance directory to enhance accessibility for patients [8] - Recent approvals for new flu drugs indicate a growing focus on pediatric formulations, with companies like Zhongsheng actively pursuing clinical trials for younger populations [7][8]

Group 1 - The article highlights the top 20 stocks in the S&P China A-Share Dividend Opportunity Index, showcasing significant daily and year-to-date gains along with their dividend yields [1] - The stock with the highest daily increase is Xue Ri Co., Ltd. (002083.SZ) with a daily gain of 10.03% and a year-to-date increase of 167.92% [1] - Weichai Power (000338.SZ) and Jiufeng Energy (605090.SH) also show strong performance with year-to-date gains of 35.42% and 29.39% respectively [1] Group 2 - The dividend yields of the top stocks range from 1.24% to 8.52%, indicating a mix of growth and income potential for investors [1] - Companies like Senma Clothing (002563.SZ) and China Shenhua (601088.SH) have notable dividend yields of 8.52% and 7.70% respectively, despite varying year-to-date performance [1] - The overall performance of these stocks suggests a positive trend in the market, with MACD golden cross signals indicating potential upward momentum [3]

Core Points - A total of 20 stocks received ratings from brokerages, with 6 stocks rated as "Buy" [1] - Among the stocks with target prices, Zhongyou Capital (000617.SZ) has the highest expected price increase of 16.19% based on the latest closing price [1][2] Company Summary - Zhongyou Capital (000617.SZ) received a "Buy" rating from Guotai Junan Securities, with a target price of 10.98 yuan and a closing price of 9.45 yuan, indicating a potential increase of 16.19% [2] - Other stocks rated as "Buy" include Rongsheng Petrochemical (002493.SZ), Jichuan Pharmaceutical (600566.SH), Haibo Innovation (688411.SH), Shiji Performance (002602.SZ), and Zhaoyi Innovation (603986.SH) [2] Industry Summary - The industries with the highest number of stocks receiving attention from brokerages are construction decoration, automotive, and non-ferrous metals [4]

Investment Rating - The investment rating for the company is "Buy" and is maintained [5]. Core Views - The company reported a significant decline in revenue and net profit for the first three quarters of 2025, with revenue of 3.932 billion yuan, down 32.27% year-on-year, and a net profit of 1.022 billion yuan, down 46.27% year-on-year [3][9]. - The third quarter of 2025 saw a revenue of 1.183 billion yuan, a decrease of 33.17% year-on-year, and a net profit of 298 million yuan, down 47.19% year-on-year [3][9]. - Despite the decline, the company is expected to see a recovery in Q4 2025 [3]. Financial Performance Summary - For the first nine months of 2025, the company achieved a gross margin of 77.68%, a decrease of 0.86 percentage points year-on-year, and a net profit margin of 25.19%, down 6.69 percentage points year-on-year [9]. - Sales expenses were effectively controlled, amounting to 362 million yuan in Q3 2025, a decrease of 37.65% year-on-year, with a sales expense ratio of 30.57% [9]. - The company has a diversified product portfolio with several products recognized in authoritative medication guidelines and clinical textbooks [9]. Earnings Forecast - The forecast for the company's net profit for 2025-2027 is 1.443 billion yuan, 1.567 billion yuan, and 1.641 billion yuan, respectively, with corresponding EPS of 1.57 yuan, 1.70 yuan, and 1.78 yuan [9].

Core Insights - The stock price of Jichuan Pharmaceutical has decreased by 2.00% as of November 13, trading at 27.43 CNY per share with a total market capitalization of 25.254 billion CNY [1] - The company has experienced a significant decline in revenue and net profit for the first nine months of 2025, with revenue down 32.27% year-on-year and net profit down 46.27% [2] Financial Performance - For the period from January to September 2025, Jichuan Pharmaceutical reported a revenue of 3.932 billion CNY and a net profit attributable to shareholders of 1.022 billion CNY [2] - The company has distributed a total of 9.227 billion CNY in dividends since its A-share listing, with 3.931 billion CNY distributed over the last three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 47,400, while the average number of circulating shares per person decreased by 7.02% to 19,370 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 500 ETF, with notable reductions in their holdings [3]

Core Insights - The article highlights the rise of domestic innovative flu medications in China, marking 2025 as a significant year for the industry, with a notable increase in flu activity reported in southern and northern provinces [1][2]. Group 1: Market Developments - A total of 347 flu-like outbreak cases were reported nationwide as of November 2, 2025, indicating a growing demand for flu medications [1]. - Several domestic innovative flu drugs have been approved this year, including "Yisuda" (Marshularsavir Tablets) and "Anruiwei" (Angladiwe Tablets), which were launched in March and May respectively [1][2]. - The innovative drug "Makexiluo Savir Tablets" was approved in July through a collaboration between Hubei Jichuan Pharmaceutical and Nanjing Zhengxiang Pharmaceutical [2]. Group 2: Industry Trends - Domestic pharmaceutical companies are actively enhancing awareness among healthcare professionals and the public regarding the characteristics of their products, indicating progress in commercialization [2]. - The market share of imported flu medications, particularly Oseltamivir, which previously dominated with over 80%, is expected to be challenged by the new domestic offerings [2][4]. Group 3: Policy Support - The development of domestic innovative drugs is supported by government policies, including measures from the National Healthcare Security Administration and the National Health Commission aimed at promoting high-quality development of innovative drugs [3]. - The policies focus on increasing support for R&D, facilitating access to basic medical insurance, and enhancing clinical application and payment capabilities for innovative drugs [3]. Group 4: Future Outlook - There is a strong intention among domestic innovative flu drug manufacturers to enter the medical insurance system, which could lead to price reductions if negotiations are successful [4]. - The rapid development of innovative flu medications is seen as a significant step for China's pharmaceutical industry, which is also expanding into other therapeutic areas such as oncology and infectious diseases [4].